TXNIP Antibody | 7941

TXNIP Antibody | 7941 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: Predicted species reactivity based on immunogen sequence: Pig: (94%)

Immunogen: TXNIP antibody was raised against a 16 amino acid peptide near the center of human TXNIP.
The immunogen is located within amino acids 110 - 160 of TXNIP.

Research Area: Cancer

Tested Application: E, WB, IHC-P, IF

Application: TXNIP body can be used for detection of TXNIP by Western blot at 0.5 - 1 μg/ml. Antibody can also be used for Immunohistochemistry at 2 μg/mL. For Immunoflorescence start at 5 μg/mL.
Antibody validated: Western Blot in mouse samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

Specificiy: TXNIP antibody is human, mouse and rat reactive.

Positive Control 1: Cat. No. 1285 - C2C12 Cell Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Predicted: 43 kDa
Observed: 39 kDa

Validation: N/A

Isoform: N/A

Purification: TXNIP antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: TXNIP antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: TXNIP antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.

Alternate Name: Thioredoxin-interacting protein, BMP and activin membrane-bound inhibitor homolog, non-metastatic gene A protein, NMA

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Thioredoxin-interacting protein (TXNIP) belongs to the arrestin family and plays a critical role in the antioxidant defense mechanisms of hematopoietic cells by activating the p53 pathway during oxidative stress (1, 2) . It functions as a transcriptional repressor and acts as an oxidative stress mediator by inhibiting thioredoxin activity (2) . TXNIP expression is reduced in many types of tumors, and TXNIP overexpression inhibits tumor growth by blocking cell-cycle progression (3) . It has recently reported that TXNIP deficiency correlates with a high incidence of hepatocellular carcinoma (HCC) (4) . TXNIP and p53 interactions could potentially be a therapeutic target for oxidative stress-related diseases such as hematopoietic malignancies and metabolic diseases (5) .